MoneycontrolMoneycontrol

Glenmark Pharma shares rise over 2% as unit files US application for experimental solid-tumour drug

3 min czytania

Shares of Glenmark Pharmaceuticals Ltd rallied over 2.5 percent in Wednesday’s trading session, November 18, after the pharmaceutical major’s innovation arm, Ichnos Glenmark Innovation (IGI), filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for its experimental cancer therapy, ISB 2301. This marks a key step towards advancing the company's oncology pipeline into clinical development, particularly in the area of solid tumours.

Glenmark Pharma shares opened at Rs 2,665, on the BSE and rallied 2.53 percent to touch an intra-day high of Rs 2,680, compared with its previous closing of Rs 2,613.80.

Glenmark seeks US FDA nod for ISB 2301 human trials

In an exchange filing on Wednesday, IGI said it has submitted an IND application to the US Food and Drug Administration (FDA) for its trispecific antibody, ISB 2301, a first-in-class cancer immunotherapy targeting solid tumours, including breast and lung cancers.

According to the New York-based biotech firm, the experimental drug, designed for the treatment of solid tumors, has demonstrated favourable safety profile in non-human primates.

It said ISB 2301 is a five-pronged antibody engineered to target three tumour markers while activating T cells and natural killer (NK) cells. This dual-action approach is designed to overcome tumour diversity and immune suppression, which often limit the effectiveness of solid-tumour treatments. Both T cells and natural killer (NK) cells are white blood cells that work together to detect and destroy cancer cells.

According to the regulatory filing, IGI plans to begin the first in human trials of the experimental drug in 2027, in line with its previously announced timeline, with a Phase 1 clinical trial in patients with solid tumours.

The study will evaluate the therapy's safety, tolerability, how it moves through the body and its early effectiveness against tumours.

"Submission of the IND for ISB 2301 marks an important milestone in advancing IGI's multispecific oncology pipeline into clinical development," IGI president and chief executive officer Lida Pacaud.

"This pentaspecific candidate is designed to integrate multiple tumour-targeting and immune-engaging functions within a single molecule. Our preclinical results have demonstrated a compelling anti-cancer profile for ISB 2301, a candidate we believe to be highly differentiated from current approaches,” Pacaud added.

How ISB 2301 works

According to the company, ISB 2301 has been developed using its proprietary BEAT (Bispecific Engagement by Antibodies based on the TCR) Multispecific Platform. The molecule combines five binding points — three cancer markers and two immune-cell triggers — allowing it to attack tumours through multiple mechanisms at once, including blocking cancer defences and sparking a broader immune response.

The company said preclinical studies in non-human primates showed favourable tolerability and drug-processing profiles, supporting its move into human trials.

The IND filing underscores IGI's efforts to leverage multispecific antibody technology in areas where treatment options remain limited.

Glenmark's oncology pipeline: ISB 2001 deal with AbbVie

IGI is already developing ISB 2001, a triple-targeting antibody for relapsed or treatment-resistant multiple myeloma that has shown encouraging results in an ongoing Phase 1 study. Ichnos has licensed ISB 2001 to US drugmaker AbbVie in a deal worth $700 million upfront and up to $1.2 billion in milestones, making it the biggest out-licensing deal by an Indian pharma company. ISB 2001 is for treating multiple myeloma, a type of blood cancer, while ISB 2301 is meant for solid tumours, which has even wider application.

SB 2301 was engineered using IGI’s proprietary BEAT® Multispecific Platform and is designed to recognize three tumor-associated antigens while engaging both T cells and NK cells through complementary mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition, and the induction of a sustained type 1 immune response.

Glenmark launches generic version of Pfizer's Inlyta in US

Earlier on Monday, Glenmark Pharmaceuticals Inc, USA, announced the launch of Axitinib Tablets in 1 mg and 5 mg strengths, a generic version of Pfizer Inc's Inlyta tablets. Glenmark Axitinib tablets (a generic equivalent to Pfizer's Inlyta) are used to treat advanced renal cell carcinoma (RCC), a type of kidney cancer.

"The launch of Axitinib tablets reinforces Glenmark's commitment to expanding access to quality, affordable medicines for patients in the United States," said Marc Kikuchi, President & Business Head, North America.

By adding this product to its portfolio, the company continues to strengthen focus on addressing the evolving needs of patients and healthcare providers, he said.

According to IQVIA sales data for the 12-month period ended September 2026, annual sales of Inlyta tablets in the US were around $538.4 million, the company said in a statement.

Glenmark Pharma share price history

Shares of Glenmark Pharma have given robust returns to its investors. In the last one month, the shares have gained over 19 percent while in three months, the stock has surged 15 percent and over 13 percent in six months, respectively.

On year-to date (YTD) basis, the stock has advanced 31 percent and 44 percent in one year, as per BSE analytics.

Wyłączenie odpowiedzialności

Przeczytaj cały artykuł
Uzyskaj nieograniczony dostęp do artykułów od Moneycontrol oraz ze wszystkich pozostałych źródeł wiadomości na TradingView.